KCNQ3 and myeloid sarcoma: In MS, we found that KCNQ3 and KCNQ5 were downregulated in L2–6 ENs (Figure 2B and Supplemental Table 6), specifically in patients with long disease duration (Figure 2D and Supplemental Table 7).